Molecular basis of protein S deficiency

Summary

Protein S deficiency (PSD) has been the most difficult to study among the classical inherited thrombophilic factors. This is in part due to the peculiar biology of protein S (PS), which has an anticoagulant role but no enzymatic activity,and because it interacts with plasma components that function in both haemostasis and inflammation.Clinically,it also has been difficult to define and standardise valuable assays to determine PS status and implication in thrombosis. Despite these drawbacks, at present heterozygous PS deficiency is well established as an autosomal dominant trait associated with an increased risk of thrombosis from data on familial and population studies. Almost twohundred mutations have been characterised in PROS1, and approximately 30% of them have been characterised in vitro,clarifying the mechanisms leading to PSD. Furthermore, recent studies on the presence of large deletions in PROS1 have increased the number of PSD associated to PROS1 mutations. Finally, the discovery of new functions for PS, both in the anticoagulant system as well as in the interaction with cellular components through receptor tyrosine kinases, is broadening the importance of this molecule in the context of biomedicine.

Keywords

Protein S - PROS1 - mutations - natural anticoagulants - thrombophilia - vitamin K

• References

• 1 DiScipio RG, Davie EW. Characterization of protein S, a gamma-carboxyglutamic acid containing protein from bovine and human plasma. Biochemistry 1979; 18: 899-904.
• 2 Walker FJ. Regulation of activated protein C by a new protein. A possible function for bovine protein S. J Biol Chem 1980; 255: 5521-5524.
• 3 Comp PC, Nixon RR, Cooper MR. et al. Familial protein S deficiency is associated with recurrent thrombosis. J Clin Invest 1984; 74: 2082-2088.
• 4 Schwarz HP, Fischer M, Hopmeier P. et al. Plasma protein S deficiency in familial thrombotic disease. Blood 1984; 64: 1297-1300.
• 5 Esmon CT. The protein C pathway. Chest 2003; 124: 26S-32S.
• 6 Dahlbäck B, Villoutreix BO. The anticoagulant protein C pathway. FEBS Lett 2005; 579: 3310-3316.
• 7 Franchini M, Veneri D. Inherited thrombophilia: an update. Clin Lab 2005; 51: 357-365.
• 8 Gandrille S, Borgel D, Sala N. et al. Protein S deficiency: a database of mutations--summary of the first update. Thromb Haemost 2000; 84: 918.
• 9 Furie B, Bouchard BA, Furie BC. Vitamin K-dependent biosynthesis of gamma-carboxyglutamic acid. Blood 1999; 93: 1798-1808.
• 10 Stenflo J. Contributions of Gla and EGF-like domains to the function of vitamin K-dependent coagulation factors. Crit Rev Eukaryot Gene Expr 1999; 9: 59-88.
• 11 Walker FJ. Regulation of vitamin K-dependent protein S. Inactivation by thrombin. J Biol Chem 1984; 259: 10335-10339.
• 12 Dahlbäck B, Lundwall A, Stenflo J. Localization of thrombin cleavage sites in the amino-terminal region of bovine protein S. J Biol Chem 1986; 261: 5111-5115.
• 13 Lu D, Xie RL, Rydzewski A. et al. The effect of N-linked glycosylation on molecular weight, thrombin cleavage, and functional activity of human protein S. Thromb Haemost 1997; 77: 1156-1163.
• 14 Long GL, Lu D, Xie RL. et al. Human protein S cleavage and inactivation by coagulation factor Xa. J Biol Chem 1998; 273: 11521-11526.
• 15 Giri TK, Villoutreix BO, Wallqvist A. et al. Topological studies of the amino terminal modules of vitamin K-dependent protein S using monoclonal antibody epitope mapping and molecular modeling. Thromb Haemost 1998; 80: 798-804.
• 16 Dahlbäck B, Hildebrand B, Malm J. Characterization of functionally important domains in human vitamin K-dependent protein S using monoclonal antibodies. J Biol Chem 1990; 265: 8127-8135.
• 17 Stenberg Y, Linse S, Drakenberg T. et al. The high affinity calcium-binding sites in the epidermal growth factor module region of vitamin K-dependent protein S. J Biol Chem 1997; 272: 23255-23260.
• 18 Nelson RM, VanDusen WJ, Friedman PA. et al. beta-Hydroxyaspartic acid and beta-hydroxyasparagine residues in recombinant human protein S are not required for anticoagulant cofactor activity or for binding to C4b-binding protein. J Biol Chem 1991; 266: 20586-20589.
• 19 Villoutreix BO, García de Frutos, Lovenklev M. et al. SHBG region of the anticoagulant cofactor protein S: secondary structure prediction, circular dichroism spectroscopy, and analysis of naturally occurring mutations. Proteins 1997; 29: 478-491.
• 20 Evenas P, García de Frutos, Linse S. et al. Both G-type domains of protein S are required for the highaffinity interaction with C4b-binding protein. Eur J Biochem 1999; 266: 935-942.
• 21 Giri TK, Linse S, García de Frutos. et al. Structural requirements of anticoagulant protein S for its binding to the complement regulator C4b-binding protein. J Biol Chem 2002; 277: 15099-15106.
• 22 Villoutreix BO, Dahlbäck B, Borgel D. et al. Threedimensional model of the SHBG-like region of anticoagulant protein S: new structure-function insights. Proteins 2001; 43: 203-216.
• 23 Giri TK, Yamazaki T, Sala N. et al. Deficient APCcofactor activity of protein S Heerlen in degradation of factor Va Leiden: a possible mechanism of synergism between thrombophilic risk factors. Blood 2000; 96: 523-531.
• 24 Drakenberg T, Ghasriani H, Thulin E. et al. Solution structure of the Ca2+-Binding EGF3–4 pair from vitamin K-dependent protein S: identification of an unusual fold in EGF3. Biochemistry 2005; 44: 8782-8789.
• 25 Fuentes-Prior P, Iwanaga Y, Huber R. et al. Structural basis for the anticoagulant activity of the thrombin- thrombomodulin complex. Nature 2000; 404: 518-525.
• 26 Hambleton S, Valeyev NV, Muranyi A. et al. Structural and functional properties of the human Notch-1 ligand binding region. Structure 2004; 12: 2173-2183.
• 27 Sasaki T, Knyazev PG, Cheburkin Y. et al. Crystal structure of a C-terminal fragment of growth arrestspecific protein Gas6 – Receptor tyrosine kinase activation by laminin G-like domains. J Biol Chem 2002; 277: 44164-44170.
• 28 Sasaki T, Knyazev PG, Clout NJ. et al. Structural basis for Gas6-Axl signalling. Embo J 2006; 25: 80-87.
• 29 Villoutreix BO, Teleman O, Dahlbäck B. A theoretical model for the Gla-TSR-EGF-1 region of the anticoagulant cofactor protein S: from biostructural pathology to species-specific cofactor activity. J Comput Aided Mol Des 1997; 11: 293-304.
• 30 Giri TK, de Frutos PG, Yamazaki T. et al. In vitro characterisation of two naturally occurring mutations in the thrombin-sensitive region of anticoagulant protein S. Thromb Haemost 1999; 82: 1627-1633.
• 31 He X, Shen L, Villoutreix BO. et al. Amino acid residues in thrombin-sensitive region and first epidermal growth factor domain of vitamin K-dependent protein S determining specificity of the activated protein C cofactor function. J Biol Chem 1998; 273: 27449-27458.
• 32 Stenberg Y, Drakenberg T, Dahlbäck B. et al. Characterization of recombinant epidermal growth factor (EGF)-like modules from vitamin-K-dependent protein S expressed in Spodoptera cells--the cofactor activity depends on the N-terminal EGF module in human protein S. Eur J Biochem 1998; 251: 558-564.
• 33 van Wijnen M, Stam JG, Chang GT. et al. Characterization of mini-protein S, a recombinant variant of protein S that lacks the sex hormone binding globulinlike domain. Biochem J 1998; 330: 389-396.
• 34 Nicolaes GA, Dahlbäck B. Factor V and thrombotic disease: description of a janus-faced protein. Arterioscler Thromb Vasc Biol 2002; 22: 530-538.
• 35 Nyberg P, Dahlbäck B, García de Frutos. The SHBG-like region of protein S is crucial for factor V-dependent APC-cofactor function. FEBS Lett 1998; 433: 28-32.
• 36 Yegneswaran S, Smirnov MD, Safa O. et al. Relocating the active site of activated protein C eliminates the need for its protein S cofactor. A fluorescence resonance energy transfer study. J Biol Chem 1999; 274: 5462-5468.
• 37 Rosing J, Tans G. Coagulation factor V: an old star shines again. Thromb Haemost 1997; 78: 427-433.
• 38 Griffin JH, Kojima K, Banka CL. et al. High-density lipoprotein enhancement of anticoagulant activities of plasma protein S and activated protein C. J Clin Invest 1999; 103: 219-227.
• 39 Xu N, Dahlbäck B, Ohlin AK. et al. Association of vitamin K-dependent coagulation proteins and C4b binding protein with triglyceride-rich lipoproteins of human plasma. Arterioscler Thromb Vasc Biol 1998; 18: 33-39.
• 40 Denis CV, Roberts SJ, Hackeng TM. et al. In vivo clearance of human protein S in a mouse model: influence of C4b-binding protein and the Heerlen polymorphism. Arterioscler Thromb Vasc Biol 2005; 25: 2209-2215.
• 41 Dahlbäck B. Protein S and C4b-binding protein: components involved in the regulation of the protein C anticoagulant system. Thromb Haemost 1991; 66: 49-61.
• 42 Rezende SM, Simmonds RE, Lane DA. Coagulation, inflammation, and apoptosis: different roles for protein S and the protein S-C4b binding protein complex. Blood 2004; 103: 1192-1201.
• 43 Hillarp A, Wiklund H, Thern A. et al. Molecular cloning of rat C4b binding protein alpha- and betachains: structural and functional relationships among human, bovine, rabbit, mouse, and rat proteins. J Immunol 1997; 158: 1315-1323.
• 44 Hillarp A, Thern A, Dahlbäck B. Bovine C4b binding protein. Molecular cloning of the alpha- and betachains provides structural background for lack of complex formation with protein S. J Immunol 1994; 153: 4190-4199.
• 45 García de Frutos, Dahlbäck B. cDNA structure of rabbit C4b-binding protein alpha-chain. Preserved sequence motive in complement regulatory protein modules which bind C4b. Biochim Biophys Acta 1995; 1261: 285-289.
• 46 Hillarp A, Dahlbäck B. Novel subunit in C4b-binding protein required for protein S binding. J Biol Chem 1988; 263: 12759-12764.
• 47 Rodriguez de Córdoba S, Perez-Blas M, Ramos-Ruiz R. et al. The gene coding for the beta-chain of C4b-binding protein (C4BPB) has become a pseudogene in the mouse. Genomics 1994; 21: 501-509.
• 48 Dahlbäck B. Inhibition of protein Ca cofactor function of human and bovine protein S by C4b-binding protein. J Biol Chem 1986; 261: 12022-12027.
• 49 Griffin JH, Gruber A, Fernández JA. Reevaluation of total, free, and bound protein S and C4b-binding protein levels in plasma anticoagulated with citrate or hirudin. Blood 1992; 79: 3203-3211.
• 50 García de Frutos, Alim RI, Hardig Y. et al. Differential regulation of alpha and beta chains of C4b-binding protein during acute-phase response resulting in stable plasma levels of free anticoagulant protein S. Blood 1994; 84: 815-822.
• 51 Heeb MJ, Mesters RM, Tans G. et al. Binding of protein S to factor Va associated with inhibition of prothrombinase that is independent of activated protein C. J Biol Chem 1993; 268: 2872-2877.
• 52 Heeb MJ, Radtke KP, Fernandez JA. et al. Plasma contains protein S monomers and multimers with similar direct anticoagulant activity. J Thromb Haemost 2006; 4: 2215-2222.
• 53 Heeb MJ, Schuck P, Xu X. Protein S multimers and monomers each have direct anticoagulant activity. J Thromb Haemost 2006; 4: 385-391.
• 54 Heeb MJ, Griffin JH. Activated protein C-dependent and -independent anticoagulant activities of protein S have different structural requirements. Blood Cells Mol Dis 2002; 29: 190-199.
• 55 van Wijnen M, Stam JG, van’t Veer C. et al. The interaction of protein S with the phospholipid surface is essential for the activated protein C-independent activity of protein S. Thromb Haemost 1996; 76: 397-403.
• 56 van Wijnen M, van’t Veer C, Meijers JC. et al. A plasma coagulation assay for an activated protein C-independent anticoagulant activity of protein S. Thromb Haemost 1998; 80: 930-935.
• 57 Koppelman SJ, van’t Veer C, Sixma JJ. et al. Synergistic inhibition of the intrinsic factor X activation by protein S and C4b-binding protein. Blood 1995; 86: 2653-2660.
• 58 Hackeng TM, Sere KM, Tans G. et al. Protein S stimulates inhibition of the tissue factor pathway by tissue factor pathway inhibitor. Proc Natl Acad Sci USA 2006; 103: 3106-3111.
• 59 Martinelli I, Mannucci PM, De SV. et al. Different risks of thrombosis in four coagulation defects associated with inherited thrombophilia: a study of 150 families. Blood 1998; 92: 2353-2358.
• 60 Manucci PM. The molecular basis of inherited thrombophilia. Vox Sang 2000; 78 (Suppl. 02) 39-45.
• 61 Simioni P, Tormene D, Spiezia L. et al. Inherited thrombophilia and venous thromboembolism. Sem Thromb Hemost 2006; 32: 700-708.
• 62 Miyata T, Kimura R, Kokubo Y. et al. Genetic risk factors for deep vein thrombosis among Japanese: importance of protein S K196E mutation. Int J Hematol 2006; 83: 217-223.
• 63 Suehisa E, Nomura T, Kawasaki T. et al. Frequency of natural coagulation inhibitor (antithrombin III, protein C and protein S) deficiencies in Japanese patients with spontaneous deep vein thrombosis. Blood Coagul Fibrinolysis 2001; 12: 95-99.
• 64 Biguzzi E, Razzari C, Lane DA. et al. Molecular diversity and thrombotic risk in protein S deficiency: the PROSIT study. Hum Mutat 2005; 25: 259-269.
• 65 Gomez E, Ledford MR, Pegelow CH. et al. Homozygous protein S deficiency due to a one base pair deletion that leads to a stop codon in exon III of the protein S gene. Thromb Haemost 1994; 71: 723-726.
• 66 Mahasandana C, Veerakul G, Tanphaichitr VS. et al. Homozygous protein S deficiency: 7-year followup. Thromb Haemost 1996; 76: 1122.
• 67 Pabinger I, Schneider B. Thrombotic risk in hereditary antithrombin III, protein C, or protein S deficiency. A cooperative, retrospective study. Gesellschaft fur Thrombose- und Hamostaseforschung (GTH) Study Group on Natural Inhibitors. Arterioscler Thromb Vasc Biol 1996; 16: 742-748.
• 68 Simmonds RE, Ireland H, Lane DA. et al. Clarification of the risk for venous thrombosis associated with hereditary protein S deficiency by investigation of a large kindred with a characterized gene defect. Ann Intern Med 1998; 128: 8-14.
• 69 Faioni EM, Valsecchi C, Palla A. et al. Free protein S deficiency is a risk factor for venous thrombosis. Thromb Haemost 1997; 78: 1343-1346.
• 70 Persson KE, Dahlbäck B, Hillarp A. Diagnosing protein S deficiency: analytical considerations. Clin Lab 2003; 49: 103-110.
• 71 Meijer P, Haverkate F, Kluft C. Performance goals for the laboratory testing of antithrombin, protein C and protein S. Thromb Haemost 2006; 96: 584-589.
• 72 Makris M, Leach M, Beauchamp NJ. et al. Genetic analysis, phenotypic diagnosis, and risk of venous thrombosis in families with inherited deficiencies of protein S. Blood 2000; 95: 1935-1941.
• 73 Brouwer JL, Veeger NJ, van der SW. et al. Difference in absolute risk of venous and arterial thrombosis between familial protein S deficiency type I and type III. Results from a family cohort study to assess the clinical impact of a laboratory test-based classification. Br J Haematol 2005; 128: 703-710.
• 74 Aiach M, Borgel D, Gaussem P. et al. Protein C and protein S deficiencies. Semin Hematol 1997; 34: 205-216.
• 75 Woodward M, Lowe GD, Rumley A. et al. Epidemiology of coagulation factors, inhibitors and activation markers: The Third Glasgow MONICA Survey. II. Relationships to cardiovascular risk factors and prevalent cardiovascular disease. Br J Haematol 1997; 97: 785-797.
• 76 Henkens CM, Bom VJ, van der SW. et al. Plasma levels of protein S, protein C, and factor X: effects of sex, hormonal state and age. Thromb Haemost 1995; 74: 1271-1275.
• 77 Dykes AC, Walker ID, McMahon AD. et al. A study of Protein S antigen levels in 3788 healthy volunteers: influence of age, sex and hormone use, and estimate for prevalence of deficiency state. Br J Haematol 2001; 113: 636-641.
• 78 Sakata T, Okamoto A, Mannami T. et al. Prevalence of protein S deficiency in the Japanese general population: The Suita Study. J Thromb Haemost 2004; 2: 1012-1013.
• 79 Brunet D, Barthet MC, Morange PE. et al. Protein S deficiency: Different biological phenotypes according to the assays used. Thromb Haemost 1998; 79: 446-447.
• 80 Giri TK, Hillarp A, Hardig Y. et al. A new direct, fast and quantitative enzyme-linked ligandsorbent assay for measurement of free protein S antigen. Thromb Haemost 1998; 79: 767-772.
• 81 Libourel EJ, Bank I, Veeger NJ. et al. Protein S type III deficiency is no risk factor for venous and arterial thromboembolism in 168 thrombophilic families: a retrospective study. Blood Coagul Fibrinolysis 2005; 16: 135-140.
• 82 Rezende SM, Lane DA, Zöller B. et al. Genetic and phenotypic variability between families with hereditary protein S deficiency. Thromb Haemost 2002; 87: 258-265.
• 83 Simmonds RE, Zöller B, Ireland H. et al. Genetic and phenotypic analysis of a large (122-member) protein S-deficient kindred provides an explanation for the familial coexistence of type I and type III plasma phenotypes. Blood 1997; 89: 4364-4370.
• 84 Espinosa-Parrilla Y, Yamazaki T, Sala N. et al. Protein S secretion differences of missense mutants account for phenotypic heterogeneity. Blood 2000; 95: 173-179.
• 85 Zöller BP, Dahlbäck B. Evaluation of the relationship between protein-S and C4B-binding protein isoforms in hereditary protein-S deficiency demonstrating type-I and type-III deficiencies to be phenotypic variants of the same genetic disease. Blood 1995; 85: 3524-3531.
• 86 Espinosa-Parrilla Y, Morell M, Souto JC. et al. Protein S gene analysis reveals the presence of a cosegregating mutation in most pedigrees with type I but not type III PS deficiency. Hum Mutat 1999; 14: 30-39.
• 87 Espinosa-Parrilla Y, Morell M, Souto JC. et al. Absence of linkage between type III protein S deficiency and the PROS1 and C4BP genes in families carrying the protein S Heerlen allele. Blood 1997; 89: 2799-2806.
• 88 Bertina RM, Ploos van Amstel HK, van Wijngaarden A. et al. Heerlen polymorphism of protein S, an immunologic polymorphism due to dimorphism of residue 460. Blood 1990; 76: 538-548.
• 89 Beauchamp NJ, Dykes AC, Parikh N. et al. The prevalence of, and molecular defects underlying, inherited protein S deficiency in the general population. Br J Haematol 2004; 125: 647-654.
• 90 Gandrille S, Aiach M. Identification of mutations in 90 of 121 consecutive symptomatic French patients with a type I protein C deficiency. The French INSERM Network on Molecular Abnormalities Responsible for Protein C and Protein S deficiencies. Blood 1995; 86: 2598-2605.
• 91 Espinosa-Parrilla Y, Morell M, Borrell M. et al. Optimization of a simple and rapid single-strand conformation analysis for detection of mutations in the PROS1 gene: identification of seven novel mutations and three novel, apparently neutral, variants. Hum Mutat 2000; 15: 463-473.
• 92 Tatewaki H, Tsuda H, Kanaji T. et al. Characterization of the human protein S gene promoter: a possible role of transcription factors Sp1 and HNF3 in liver. Thromb Haemost 2003; 90: 1029-1039.
• 93 Hall AJ, Peake IR, Winship PR. Regulation of the human protein S gene promoter by liver enriched transcription factors. Br J Haematol 2006; 135: 538-546.
• 94 de Wolf CJ, Cupers RM, Bertina RM. et al. Interleukin- 6 induction of protein s is regulated through signal transducer and activator of transcription 3. Arterioscler Thromb Vasc Biol 2006; 26: 2168-2174.
• 95 de Wolf CJ, Cupers RM, Bertina RM. et al. The constitutive expression of anticoagulant protein S is regulated through multiple binding sites for Sp1 and Sp3 transcription factors in the protein S gene promoter. J Biol Chem 2006; 281: 17635-17643.
• 96 Lanke E, Johansson AM, Hillarp A. et al. Co-segregation of the PROS1 locus and protein S deficiency in families having no detectable mutations in PROS1. J Thromb Haemost 2004; 2: 1918-1923.
• 97 Johansson AM, Hillarp A, Sall T. et al. Large deletions of the PROSI gene in a large fraction of mutationnegative patients with protein S deficiency. Thromb Haemost 2005; 94: 951-957.
• 98 Heinikari T, Huoponen O, Partanen J. et al. Protein S gene polymorphisms Pro626 and nt2698--no correlation to free protein S levels or protein S activities. Thromb Haemost 2005; 94: 1340-1341.
• 99 Mustafa S, Pabinger I, Mannhalter C. Protein S deficiency type I: identification of point mutations in 9 of 10 families. Blood 1995; 86: 3444-3451.
• 100 Reitsma PH, Vanamstel HKP, Bertina RM. 3 Novel Mutations in 5 Unrelated Subjects with Hereditary Protein-S Deficiency Type-1. J Clin Invest 1994; 93: 486-492.
• 101 Yamazaki T, Hamaguchi M, Katsumi A. et al. A quantitative protein-S deficiency associated with a novel nonsense mutation and markedly reduced levels of mutated messenger-Rna. Thromb Haemost 1995; 74: 590-595.
• 102 Maquat LE. Nonsense-mediated mRNA decay: Splicing, translation and mRNP dynamics. Nature Rev Mol Cell Biol 2004; 5: 89-99.
• 103 Yamazaki T, Katsumi A, Kagami K. et al. Molecular basis of a hereditary type I protein S deficiency caused by a substitution of Cys for Arg474. Blood 1996; 87: 4643-4650.
• 104 ten Kate MK, Mulder R, Platteel M. et al. Identification of a novel PROS1 c.1113T-->GG frameshift mutation in a family with mixed type I/type III protein S deficiency. Haematologica 2006; 91: 1151-1152.
• 105 Giri TK, García de Frutos, Dahlbäck B. Protein S Thr103Asn mutation associated with type II deficiency reproduced in vitro and functionally characterised. Thromb Haemost 2000; 84: 413-419.
• 106 Okada H, Yamazaki T, Takagi A. et al. In vitro characterization of missense mutations associated with quantitative protein S deficiency. J Thromb Haemost 2006; 4: 2003-2009.
• 107 Tsuda H, Urata M, Tsuda T. et al. Four missense mutations identified in the protein S gene of thrombosis patients with protein S deficiency: effects on secretion and anticoagulant activity of protein S. Thromb Res 2002; 105: 233-239.
• 108 Espinosa-Parrilla Y, Navarro G, Morell M. et al. Homozygosity for the protein S Heerlen allele is associated with type I PS deficiency in a thrombophilic pedigree with multiple risk factors. Thromb Haemost 2000; 83: 102-106.
• 109 Duchemin J, Gandrille S, Borgel D. et al. The Ser 460 to Pro substitution of the protein-S-alpha (Pros1) gene is a frequent mutation associated with free protein- S (type-Iia) deficiency. Blood 1995; 86: 3436-3443.
• 110 Esparza-Gordillo J, Soria JM, Buil A. et al. Genetic determinants of variation in the plasma levels of the C4b-binding protein (C4BP) in Spanish families. Immunogenetics 2003; 54: 862-866.
• 111 Criado-García O, González-Rubio C, López-Trascasa M. et al. Modulation of C4b-binding protein isoforms during the acute phase response caused by orthopedic surgery. Haemostasis 1997; 27: 25-34.
• 112 Morboeuf O, Aiach M, Gandrille S. Lack of sequence variations in the C4b-BP beta-chain in patients with type III protein S deficiency bearing the Ser 460 to Pro mutation: description of two new intragenic isomorphisms in the C4b-BP beta-chain gene (C4BPB). Br J Haematol 1998; 101: 10-15.
• 113 Leroy-Matheron C, Gouault-Heilmann M, Aiach M. et al. A mutation of the active protein S gene leading to an EGF1-lacking protein in a family with qualitative (type II) deficiency. Blood 1998; 91: 4608-4615.
• 114 Baroni M, Mazzola G, Kaabache T. et al. Molecular bases of type II protein S deficiency: the I203-D204 deletion in the EGF4 domain alters GLA domain function. J Thromb Haemost 2006; 4: 186-191.
• 115 Rockwell NC, Thorner JW. The kindest cuts of all: crystal structures of Kex2 and furin reveal secrets of precursor processing. Trends Biochem Sci 2004; 29: 80-87.
• 116 Simmonds RE, Ireland H, Kunz G. et al. Identification of 19 protein S gene mutations in patients with phenotypic protein S deficiency and thrombosis. Protein S Study Group. Blood 1996; 88: 4195-4204.
• 117 Razzari C, Franchi F, Biguzzi E. Protein S binding to phospholipids: evaluation of eight variants of recombinant human protein S from the PROSIT study. J Thromb Haemost 2006; 4: 273-274.
• 118 Rezende SM, Lane DA, Mille-Baker B. et al. Protein S Gla-domain mutations causing impaired Ca2+-induced phospholipid binding and severe functional protein S deficiency. Blood 2002; 100: 2812-2819.
• 119 Boinot C, Borgel D, Kitzis A. et al. Familial thrombophilia is an oligogenetic disease: involvement of the prothrombin G20210A, PROC and PROS gene mutations. Blood Coagul Fibrinolysis 2003; 14: 191-196.
• 120 Franchi F, Viscardi Y, Razzari C. et al. c.301C > T (p.Arg101Cys): a novel mutation in the thrombin-sensitive region of protein S associated with a dysfunctional protein. Thromb Haemost 2006; 96: 381-383.
• 121 Borgel D, Duchemin J, Alhenc-Gelas M. et al. Molecular basis for protein S hereditary deficiency: genetic defects observed in 118 patients with type I and type IIa deficiencies. The French Network on Molecular Abnormalities Responsible for Protein C and Protein S Deficiencies. J Lab Clin Med 1996; 128: 218-227.
• 122 Okada H, Takagi A, Murate T. et al. Identification of protein Salpha gene mutations including four novel mutations in eight unrelated patients with protein S deficiency. Br J Haematol 2004; 126: 219-225.
• 123 Hermida J, Faioni EM, Mannucci PM. Poor relationship between phenotypes of protein S deficiency and mutations in the protein S alpha gene. Thromb Haemost 1999; 82: 1634-1638.
• 124 Beauchamp NJ, Daly ME, Cooper PC. et al. Molecular basis of protein S deficiency in three families also showing independent inheritance of factor V leiden. Blood 1996; 88: 1700-1707.
• 125 Andersen BD, Bisgaard ML, Lind B. et al. Characterization and structural impact of five novel PROS1 mutations in eleven protein S-deficient families. Thromb Haemost 2001; 86: 1392-1399.
• 126 Formstone CJ, Wacey AI, Berg LP. et al. Detection and characterization of seven novel protein S (PROS) gene lesions: evaluation of reverse transcript-polymerase chain reaction as a mutation screening strategy. Blood 1995; 86: 2632-2641.
• 127 Persson KE, Stenflo J, Linse S. et al. Binding of calcium to anticoagulant protein S: role of the fourth EGF module. Biochemistry 2006; 45: 10682-10689.
• 128 Iwaki T, Mastushita T, Kobayashi T. et al. DNA sequence analysis of protein S deficiency--identification of four point mutations in twelve Japanese subjects. Semin Thromb Hemost 2001; 27: 155-160.
• 129 Hayashi T, Nishioka J, Shigekiyo T. et al. Protein S Tokushima: abnormal molecule with a substitution of Glu for Lys-155 in the second epidermal growth factorlike domain of protein S. Blood 1994; 83: 683-690.
• 130 Yamazaki T, Sugiura I, Matsushita T. et al. A phenotypically neutral dimorphism of protein S: the substitution of Lys155 by Glu in the second EGF domain predicted by an A to G base exchange in the gene. Thromb Res 1993; 70: 395-403.
• 131 Kimura R, Kokubo Y, Miyashita K. et al. Polymorphisms in vitamin K-dependent gamma-carboxylationrelated genes influence interindividual variability in plasma protein C and protein S activities in the general population. Int J Hematol 2006; 84: 387-397.
• 132 Hayashi T, Nishioka J, Suzuki K. Molecular mechanism of the dysfunction of protein S(Tokushima) (Lys155-->Glu) for the regulation of the blood coagulation system. Biochim Biophys Acta 1995; 1272: 159-167.
• 133 Bustorff TC, Freire I, Gago T. et al. Identification of three novel mutations in hereditary protein S deficiency. Thromb Haemost 1997; 77: 21-25.
• 134 Duchemin J, Borg JY, Borgel D. et al. Five novel mutations of the protein S active gene (PROS 1) in 8 Norman families. Thromb Haemost 1996; 75: 437-444.
• 135 Evenas P, García de Frutos, Nicolaes GA. et al. The second laminin G-type domain of protein S is indispensable for expression of full cofactor activity in activated protein C-catalysed inactivation of factor Va and factor VIIIa. Thromb Haemost 2000; 84: 271-277.
• 136 Heeb MJ, Kojima Y, Rosing J. et al. C-terminal residues 621–635 of protein S are essential for binding to factor Va. J Biol Chem 1999; 274: 36187-36192.
• 137 Borgel D, Jude B, Aiach M. et al. First case of sporadic protein S deficiency due to a novel candidate mutation, Ala 484-->Pro, in the protein S active gene (PROS1). Thromb Haemost 1996; 75: 883-886.
• 138 Nicolaes GA, Hackeng TM, Segers K. et al. A structural model of the SHBG domain of human variant protein S Heerlen. Thromb Haemost 2006; 96: 538-540.
• 139 Koenen RR, Gomes L, Tans G. et al. The Ser460Pro mutation in recombinant protein S Heerlen does not affect its APC-cofactor and APC-independent anticoagulant activities. Thromb Haemost 2004; 91: 1105-1114.
• 140 Heeb MJ, Koenen RR, Fernández JA. et al. Direct anticoagulant activity of protein S-C4b binding protein complex in Heerlen heterozygotes and normals. J Thromb Haemost 2004; 2: 1766-1773.
• 141 Greengard JS, Fernandez JA, Radtke KP. et al. Identification of candidate residues for interaction of protein S with C4b binding protein and activated protein C. Biochem J 1995; 305: 397-403.
• 142 Fuentes-Prior P, Fujikawa K, Pratt KP. New insights into binding interfaces of coagulation factors V and VIII and their homologues lessons from high resolution crystal structures. Curr Protein Pept Sci 2002; 3: 313-339.
• 143 Li M, Long GL. Identification of two novel point mutations in the human protein S gene associated with familial protein S deficiency and thrombosis. Arterioscler Thromb Vasc Biol 1996; 16: 1407-1415.
• 144 Mustafa S, Mannhalter C, Rintelen C. et al. Clinical features of thrombophilia in families with gene defects in protein C or protein S combined with factor V Leiden. Blood Coagul Fibrinolysis 1998; 9: 85-89.
• 145 Salomon O, Steinberg DM, Zivelin A. et al. Single and combined prothrombotic factors in patients with idiopathic venous thromboembolism: prevalence and risk assessment. Arterioscler Thromb Vasc Biol 1999; 19: 511-518.
• 146 Brugge JM, Tans G, Rosing J. et al. Protein S levels modulate the activated protein C resistance phenotype induced by elevated prothrombin levels. Thromb Haemost 2006; 95: 236-242.
• 147 Kanaji T, Watanabe K, Hattori S. et al. Factor XII gene (F12) –4C/C polymorphism in combination with low protein S activity is associated with deep vein thrombosis. Thromb Haemost 2006; 96: 854-855.
• 148 Zöller B, García de Frutos, Dahlbäck B. A common 4G allele in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene as a risk factor for pulmonary embolism and arterial thrombosis in hereditary protein S deficiency. Thromb Haemost 1998; 79: 802-807.
• 149 Esmon NL, Safa O, Smirnov MD. et al. Antiphospholipid antibodies and the protein C pathway. J Autoimmun 2000; 15: 221-225.
• 150 Rand JH. The antiphospholipid syndrome. Annu Rev Med 2003; 54: 409-424.
• 151 Wu O, Robertson L, Langhorne P. et al. Oral contraceptives, hormone replacement therapy, thrombophilias and risk of venous thromboembolism: a systematic review. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) Study. Thromb Haemost 2005; 94: 17-25.
• 152 Mosnier LO, Zlokovic BV, Griffin JH. The cytoprotective protein C pathway. Blood 2007; 109: 3161-3172.
• 153 Liu D, Guo H, Griffin JH. et al. Protein S confers neuronal protection during ischemic/hypoxic injury in mice. Circulation 2003; 107: 1791-1796.
• 154 Esmon CT. Crosstalk between inflammation and thrombosis. Maturitas 2004; 47: 305-314.
• 155 Smiley ST, Boyer SN, Heeb MJ. et al. Protein S is inducible by interleukin 4 in T cells and inhibits lymphoid cell procoagulant activity. Proc Natl Acad Sci USA 1997; 94: 11484-11489.
• 156 Rigby AC, Grant MA. Protein S: a conduit between anticoagulation and inflammation. Crit Care Med 2004; 32: S336-S341.
• 157 Hafizi S, Dahlbäck B. Gas6 and protein S. Vitamin K-dependent ligands for the Axl receptor tyrosine kinase subfamily. FEBS J 2006; 273: 5231-5244.
• 158 Prasad D, Rothlin CV, Burrola P. et al. TAM receptor function in the retinal pigment epithelium. Mol Cell Neurosci 2006; 33: 96-108.
• 159 Anderson HA, Shacter E. Natural anticoagulant proteins in the regulation of autoimmunity: potential role of protein S. Curr Pharm Des 2004; 10: 929-937.
• 160 Benzakour O, Kanthou C. The anticoagulant factor, protein S, is produced by cultured human vascular smooth muscle cells and its expression is up-regulated by thrombin. Blood 2000; 95: 2008-2014.